Adam Thomas

[MOMA Therapeutics @moma_tx]

We're pleased to share that we’ve dosed the first patient in the Phase 1 trial of MOMA-341, a potent oral Werner helicase inhibitor discovered with our KNOMATIC™ platform, for advanced MSI-H/dMMR tumors. Read more: https://t.co/3qYkp38Tqx

[MOMA Therapeutics @moma_tx]

Congrats to MOMAte, Kayla Duval, on completing the @bostonmarathon! Kayla’s dedication to fundraising is just as strong as her dedication to her work @ MOMA as a Scientist. We’re proud of her not only for this major accomplishment, but for raising $10k for Mass General Hospital.

[MOMA Therapeutics @moma_tx]

We're pleased to share upcoming poster presentations @ #AACR25! Jordan Krall, Ph.D., Allison Drew & Amita Patnaik, M.D. will each share recent research and progress w/ the #oncology community in Chicago next week. Read more about the posters: https://t.co/ZhxEQPQ2sT

[MOMA Therapeutics @moma_tx]

We're pleased to announce Susan Pandya, M.D. has joined as an independent board of directors member w/ ~20 yrs of experience in #oncology #drugdevelopment. We look forward to her guidance as we advance our portfolio. Welcome to the team! Read more: https://t.co/ELMFnxwyUV

[Adam Thomas @adamthomasHR]

@moma_tx Exciting news for MOMA!

[MOMA Therapeutics @moma_tx]

Today, the MOMA team is excited to share a corporate update, including news of an exclusive in-licensing agreement for a development-stage, next-generation, & selective PARP1 inhibitor, MOMA-989, a clinical path for MOMA-341, and updates on MOMA-313. https://t.co/WoslylBjhx

[MOMA Therapeutics @moma_tx]

We're proud to be named one of @biospace's Best Places to Work 2025—for the second year in a row! At MOMA, our core values drive everything we do. This recognition reflects our commitment to a workplace where innovation, collaboration, and passion thrive. https://t.co/XiYFtj11AH

[MOMA Therapeutics @moma_tx]

We're excited to share that our CEO, Asit Parikh, will be at two upcoming investor conferences, speaking on a panel at the Guggenheim Global Healthcare Conference 2024 & presenting at the @Piper_Sandler 36th Annual Healthcare Conference. Read more: https://t.co/uG4OJeALLG

[MOMA Therapeutics @moma_tx]

Our team comprises seasoned leadership, a highly specialized workforce with deep expertise in D&D & unparalleled drive to deliver. Listen to MOMA CEO, Asit Parikh, M.D., Ph.D., below for more on our differentiating factors.

[MOMA Therapeutics @moma_tx]

Sending a warm MOMA welcome to Audrey Hecht as our newest Senior Research Associate I! MOMAtes have a unique sense of courage, each bringing sharp expertise to the table & Audrey is no exception. We admire her deep curiosity and look forward to having her on our team.

[MOMA Therapeutics @moma_tx]

Today we shared a strategic collaboration & exclusive license agreement w/ @Bayer to develop a small molecule #oncology candidate based on our proprietary KNOMATIC™ platform, further validating the power of our platform. Read more: https://t.co/kLsNstLD5C

[Adam Thomas @adamthomasHR]

@moma_tx Inspiring story

[MOMA Therapeutics @moma_tx]

This #NationalHereditaryCancerWeek, we reflect on the #1FORCECommunity & Susan Feinberg, a #HereditaryCancer patient who shared her story - reminding us the importance of our collective mission. For more info on Hereditary Cancer & FORCE, visit: https://t.co/sQKjq5qyjr

[MOMA Therapeutics @moma_tx]

As a clinical-stage company, we have a responsibility to pursue the power of highly dynamic proteins that underlie human disease rapidly & efficiently for patients. Hear from MOMAtes on what this means to us & how we’re committed to evolving in rhythm w/ company growth.

[Adam Thomas @adamthomasHR]

@moma_tx Congratulations to Asit Parikh and every MOMAte on achieving this important milestone! I am excited to be working on getting the next generation of cancer therapies to patients.

[MOMA Therapeutics @moma_tx]

What are highly dynamic proteins? Highly dynamic proteins - often called "molecular machines” - drive many cellular processes that underlie human disease. We're focusing on the potential of this target class with two wholly-owned lead oncology assets. Learn more below.

[Adam Thomas @adamthomasHR]

@moma_tx Delighted to be onboard at @moma_tx.

[Aoifemlbrennan @aoifemlbrennan]

We just had to do Bernie minding the @synlogic_tx office.

[Michele Perry @maperry44]

@BiotechGames Team E. colicious is reporting for duty to defend the title for @synlogic_tx !!!#keepthebear #fraxagames2020 #trivia

[Aoifemlbrennan @aoifemlbrennan]

I am proud of the team for staying focused and delivering and looking forward to seeing what more the Synlogic platform can do. 14/14